Payment overview · 2025
General Payments
$3,115.33
95 reported records · 28 companies
Healthcare provider profile · identity verified
Kenneth S Sharlin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OZARK, MO · NPI 1790749182
Verified facts
What the public records show
CMS Open Payments records show Kenneth S Sharlin, MD received $3,115.33 in general payments during 2025 across 95 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ongentys by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nurtec Odt by this doctor in 2024.
Tanabe Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Radicava ORS as an associated drug or biological on 38 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Radicava Ors by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $1,177.24 | 37.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $217.79 | 7.0% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $213.88 | 6.9% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $159.92 | 5.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $127.85 | 4.1% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $124.30 | 4.0% | 7 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $108.23 | 3.5% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.48 | 3.4% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $89.69 | 2.9% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $87.80 | 2.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.81 | 2.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.69 | 2.6% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $52.13 | 1.7% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $47.00 | 1.5% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$45.85 | 1.5% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $44.98 | 1.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $42.07 | 1.4% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $40.60 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.50 | 1.3% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $37.32 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.73 | 1.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.53 | 0.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.76 | 0.9% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.09 | 0.8% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $24.01 | 0.8% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $19.59 | 0.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.16 | 0.5% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.33 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,938.09 | 94 |
| Travel and Lodging | $1,177.24 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $213.88 | 9 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $159.92 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $127.85 | 12 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $124.30 | 7 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $108.23 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.42 | 11 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $104.48 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $89.69 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $67.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $52.13 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $47.00 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.07 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $42.07 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $40.74 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Tanabe Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | Radicava ORS open payments reported associated product |
CMS Open Payments — General Payments 38 supporting records · 8 recipient NPIs · example record 1243917980 |
Radicava Ors · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Progesterone | Progesterone, Micronized | 307 | 54 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 238 | 42 |
| Levetiracetam | Levetiracetam | 97 | 13 |
| Pregabalin | Pregabalin | 97 | 19 |
| Estradiol | Estradiol | 94 | 21 |
| Lamotrigine | Lamotrigine | 86 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 85 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 14 |
| Aimovig Autoinjector | Erenumab-Aooe | 80 | suppressed |
| Primidone | Primidone | 77 | 12 |
| Topiramate | Topiramate | 72 | 13 |
| Gabapentin | Gabapentin | 63 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 61 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | suppressed |
| Baclofen | Baclofen | 48 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 43 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Ubrelvy | Ubrogepant | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 11 |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Fingolimod | Fingolimod Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Kesimpta Pen | Ofatumumab | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Ongentys | Opicapone | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 14 |
| Clobazam | Clobazam | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Sunosi | Solriamfetol Hcl | 12 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Radicava Ors | Edaravone | 11 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,115.33 · 95 records | E.R. Squibb & Sons, L.L.C. | ACTHAR, AUSTEDO XR, BRIUMVI, CREXONT, EMGALITY, Gocovri, HYQVIA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, REXULTI, Radicava, UBRELVY, VYALEV, VYEPTI, VYVGART HYTRULO, XYWAV, ZAVZPRET, ZEPOSIA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error